Merck-Schering Merger Requires Divestiture of Phase II Antiemetic Due To Emend's Strength
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC says Schering must divest its NK-1 receptor antagonist relapitant. Merck must also sell its interest in a $2.6 billion animal health joint venture.
You may also be interested in...
NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.
Merck Products Give Ono Pharma Renewed Life In Japan
TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company
Merck Products Give Ono Pharma Renewed Life In Japan
TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company